LifeCore Biomedical Changes Certifying Accountant
Ticker: LFCR · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1005286
| Field | Detail |
|---|---|
| Company | Lifecore Biomedical, Inc. \De\ (LFCR) |
| Form Type | 8-K |
| Filed Date | Aug 18, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, 8-K
TL;DR
LifeCore Biomedical swapped auditors, filing an 8-K on 8/18/25 for events on 8/12/25.
AI Summary
LifeCore Biomedical, Inc. (formerly Landec Corp) filed an 8-K on August 18, 2025, reporting a change in its certifying accountant as of August 12, 2025. The company, incorporated in Delaware with its principal executive offices in Chaska, Minnesota, is in the pharmaceutical preparations industry.
Why It Matters
A change in a company's auditor can signal potential shifts in financial reporting or internal controls, warranting investor attention.
Risk Assessment
Risk Level: low — This filing solely concerns a change in the company's auditor, which is a routine administrative event.
Key Players & Entities
- LIFECORE BIOMEDICAL, INC. (company) — Registrant
- LANDEC CORP (company) — Former company name
- August 12, 2025 (date) — Date of earliest event reported
- August 18, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Chaska, Minnesota (location) — Principal executive offices
FAQ
What is the primary reason for the change in LifeCore Biomedical's certifying accountant?
The filing does not specify the reason for the change in certifying accountant, only that it occurred as of August 12, 2025.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 12, 2025.
What was LifeCore Biomedical, Inc. formerly known as?
LifeCore Biomedical, Inc. was formerly known as LANDEC CORP.
In which state is LifeCore Biomedical, Inc. incorporated?
LifeCore Biomedical, Inc. is incorporated in Delaware.
What is the address of LifeCore Biomedical, Inc.'s principal executive offices?
The address of LifeCore Biomedical, Inc.'s principal executive offices is 3515 Lyman Boulevard, Chaska, Minnesota 55318.
Filing Stats: 1,291 words · 5 min read · ~4 pages · Grade level 17.8 · Accepted 2025-08-18 16:31:55
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share LFCR The NASDAQ Global Select
Filing Documents
- lndc-20250812.htm (8-K) — 34KB
- lfcr2025-08x18ex161bdolett.htm (EX-16.1) — 3KB
- 0001005286-25-000118.txt ( ) — 153KB
- lndc-20250812.xsd (EX-101.SCH) — 2KB
- lndc-20250812_lab.xml (EX-101.LAB) — 21KB
- lndc-20250812_pre.xml (EX-101.PRE) — 12KB
- lndc-20250812_htm.xml (XML) — 3KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant. Engagement of New Independent Registered Public Accounting Firm On August 12, 2025, the Audit Committee of the Board of Directors (the "Audit Committee") of Lifecore Biomedical (the "Company") concluded its process to select the Company's independent registered public accounting firm for the Company's transition period beginning May 26, 2025 and ending December 31, 2025. Based on its review and evaluation, on August 12, 2025, the Audit Committee approved the appointment of KPMG LLP ("KPMG") as the Company's independent registered public accounting firm for the transition period ending December 31, 2025. During the fiscal years ended May 26, 2024 and May 25, 2025, and during the subsequent interim period through August 12, 2025, neither the Company nor anyone on its behalf consulted with KPMG regarding: (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report or oral advice was provided to the Company that KPMG concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K, or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K. Dismissal of Independent Registered Public Accounting Firm On August 12, 2025, the Audit Committee approved the dismissal of BDO USA, P.C. ("BDO"), the Company's current independent registered public accounting firm, and BDO was dismissed on that date. BDO's audit reports on the Company's consolidated financial statements as of and for the fiscal years ended May 26, 2024 and May 25, 2025 did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to unc
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 16 Letter from BDO USA, P.C. dated August 18 , 2025 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 18, 2025 LIFECORE BIOMEDICAL, INC. By: /s/ Ryan D. Lake Ryan D. Lake Chief Financial Officer